HER3-Binding Antibody Cell Line for Cancer Therapy Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies targeting HER3 expression in cancers are limited by resistance and inefficacy, particularly in tumors refractory to anti-PD-1 therapy, where HER3 upregulation contributes to treatment resistance and progression.
Innovation Solution
A cell line expressing a HER3-binding antibody, 10D1F hIgG1, is developed, which binds specifically to HER3 with high affinity, inhibiting signaling and promoting degradation, and is used to produce antigen-binding molecules for therapeutic applications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If HER3-binding antibodies are used to target HER3 in cancers, then HER3-mediated signaling is inhibited, but treatment resistance develops and efficacy is limited
Solution Approach 1:
The invention segments the HER3 target into multiple distinct epitopes (e.g., extracellular domain epitopes versus intracellular domain epitopes). By raising antibodies against multiple different epitopes on HER3, the patent creates a diversified approach that prevents tumor cells from developing resistance through a single mechanism, thereby improving treatment reliability while addressing the adaptability problem of resistance.
Solution Approach 2:
The patent employs a composite strategy by combining multiple HER3-specific antibodies with different binding specificities and mechanisms of action. This composite approach includes antibodies that block ligand binding, antibodies that induce receptor internalization, and antibodies that recruit immune cells, creating a multi-faceted therapeutic regimen that overcomes resistance and enhances overall treatment efficacy.
2Adaptability or versatility
If multiple HER3-specific antibodies are produced to overcome resistance, then treatment versatility improves, but manufacturing complexity increases
Solution Approach 1:
The patent utilizes genetically engineered mammalian cell lines (such as CHO cells) that have been stably transfected with the genetic sequences encoding the desired HER3-specific antibodies. These cell lines serve as self-service manufacturing platforms, automatically producing the therapeutic antibodies through their normal protein synthesis machinery when cultured under appropriate conditions, thereby simplifying the manufacturing process despite the complexity of producing multiple antibody types.
Solution Approach 2:
The invention employs parameter changes in the form of different expression vectors and culture conditions to optimize the production of multiple HER3-specific antibodies. By adjusting parameters such as promoter strength, cell line genotype, medium composition, and cultivation parameters (temperature, pH, dissolved oxygen), the patent achieves efficient production of multiple antibody variants from engineered cell lines, managing manufacturing complexity while maintaining treatment versatility.
Data Source
AI summary
Cells expressing HER3 antigen-binding molecules are disclosed. Also disclosed are compositions comprising such cells, methods for producing HER3 antigen-binding molecules using such cells, and compositions comprising and methods using the HER3 antigen-binding molecules expressed by such cells.